Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regime

Trial Details

NCT ID
NCT07341867
Phase
PHASE1
Sponsor
Andrew Hantel, MD
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Dexamethasone
  • Bortezomib
  • LENALIDOMIDE
  • Daratumumab
  • Carboplatin
  • Paclitaxel
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Diagnosis of:
  • Cohort 1: MM, based on IMWG criteria12, and currently requires treatment
  • Cohort 2: Stage II or III TNBC, with definition per protocol Section 3.2.1 AND
  • Plan for treatment, per their treating physician, or currently receiving their first cycle (see 3.3.3 for definition) of:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →